cancer research aims and objectives

National Cancer Institute Overview and Mission

Driving Discovery

NCI drives the cancer research enterprise by supporting and convening researchers, paying for facilities and systems, coordinating the National Cancer Program, and more.

The National Cancer Institute (NCI) is the federal government's principal agency for cancer research and training.

Our team of approximately 3,500 is part of the National Institutes of Health (NIH), one of 11 agencies that make up the Department of Health and Human Services (HHS). NCI is deeply committed to the core values of equity, diversity, and inclusion that allow all staff to reach their potential and fully contribute to the institute’s cancer mission. See our Visitor Information for location and directions.

NCI Mission

NCI leads, conducts, and supports cancer research across the nation to advance scientific knowledge and help all people live longer, healthier lives.

NCI Leads the National Cancer Program

As the leader of the cancer research enterprise, collectively known as the National Cancer Program, and the largest funder of cancer research in the world, NCI manages a broad range of research, training, and information dissemination activities that reach across the entire country, meeting the needs of all demographics—rich and poor, urban and rural, and all racial/ethnic populations. Specifically, NCI focuses on two broad roles:

Cancer Research

• Leads the nation’s research efforts to improve cancer prevention, detection, diagnosis, and survivorship
• Supports 72 NCI-Designated Cancer Centers and more than 5,000 grantees
• Coordinates and supports all phases of clinical trials across 3,100 clinical trial sites nationwide, seeking the development of new and improved cancer treatments

• Supports intramural research scientists in our own laboratories and clinics
• Partners with industry, private philanthropic organizations, other federal agencies, and other national and foreign institutions to engage in cancer research and training opportunities that otherwise might not be possible because of their complexity and cost
• Collaborates with private-sector life sciences companies to advance promising innovative technologies that fuel improvements in detection, diagnosis, and treatment of cancer
• Supports the Frederick National Laboratory for Cancer Research , the only federally funded research and development center dedicated exclusively to biomedical research
• Maintains long-term storage of publicly available cancer genomic and clinical data
• Supports construction of laboratories, clinics, and related facilities for cancer research

Training and Support for Cancer Researchers

• Strives to attract, train, and retain the best minds to become the next generation of cancer researchers
• Provides support to scientists and their institutions to create outstanding environments for researchers to train, conduct basic and clinical research, and care for cancer patients
• Funds training and career development opportunities across a broad spectrum of cancer research disciplines through training grants, fellowships, research career development awards, and research education grants
• Supports targeted cancer research training for individuals from backgrounds underrepresented in the biomedical and behavioral sciences to achieve and sustain a diverse workforce
• Provides comprehensive training programs that support the needs of qualified individuals at all stages of their career development, ranging from middle-school students to independent researchers
• Offers training opportunities centered in hospitals and research institutions across the nation, in addition to intramural training programs offered at NCI laboratories and offices in Maryland

How NCI Is Funded and Whom We Fund

As a federal agency, NCI receives its funds from Congress. The bulk of our budget supports extramural grants and cooperative agreements to facilitate research conducted at universities, medical schools, hospitals, cancer centers, research laboratories, and private firms in the United States and abroad. These funds also support intramural research at NCI’s laboratories and offices in Bethesda, Rockville, and Frederick, MD. See the NCI Budget Fact Book for a summary of NCI’s expenditures among various research programs and funding mechanisms.

NCI’s Impact

Our investments have led to declines in the rates of new cancer cases and cancer deaths overall in the last few decades in the United States. In line with this improvement, the number of cancer survivors in the United States has more than doubled from 7 million in 1992 to more than 18 million in 2018—and is expected to rise to 26 million by 2040. These trends reflect advances in cancer detection, diagnosis, and patient care that have resulted in people living longer, healthier lives than ever before.

Together we are beating cancer

About cancer

Cancer types

• Breast cancer
• Bowel cancer
• Lung cancer
• Prostate cancer

Cancers in general

• Clinical trials

Causes of cancer

Coping with cancer

• Managing symptoms and side effects
• Mental health and cancer
• Money and travel
• Death and dying
• Cancer Chat forum

Health Professionals

• Cancer Statistics
• Cancer Screening
• Learning and Support
• NICE suspected cancer referral guidelines

Get involved

• Make a donation

By cancer type

• Leave a legacy gift
• Donate in Memory

Find an event

• Race for Life
• Charity runs
• Charity walks
• Search events
• Relay For Life
• Volunteer in our shops
• Help at an event
• Help us raise money
• Campaign for us

Do your own fundraising

• Fundraising ideas
• Get a fundraising pack
• Return fundraising money
• Fundraise by cancer type
• Set up a Cancer Research UK Giving Page
• Find a shop or superstore
• Become a partner
• Cancer Research UK for Children & Young People
• Our We Are campaign

Our research

• Brain tumours
• Skin cancer
• All cancer types

By cancer topic

• New treatments
• Cancer biology
• Cancer drugs
• All cancer subjects
• All locations
• Our achievements timeline
• Our research strategy
• Involving animals in research

Funding for researchers

Research opportunities

• For discovery researchers
• For clinical researchers
• For population researchers
• In drug discovery & development
• In early detection & diagnosis
• For students & postdocs

Our funding schemes

• Career Development Fellowship
• Discovery Programme Awards
• Clinical Trial Award
• Biology to Prevention Award
• View all schemes and deadlines

Applying for funding

• Start your application online
• How to make a successful application
• Funding committees
• Successful applicant case studies

How we deliver research

• Our research infrastructure
• Events and conferences
• Our research partnerships
• Facts & figures about our funding
• Patient involvement toolkit for researchers
• Develop your research career
• Recently funded awards
• Manage your research grant
• Notify us of new publications

Find a shop

• Volunteer in a shop
• Donate goods to a shop
• Our superstores

Shop online

• Wedding favours
• Cancer Care
• Flower Shop

Our eBay store

• Shoes and boots
• Bags and purses
• We beat cancer
• We fundraise
• We develop policy
• Our global role

Our organisation

• Our strategy
• Our Trustees
• CEO and Executive Board
• How we spend your money
• Early careers

Cancer news

• Cancer News
• For Researchers
• For Supporters
• Press office
• Publications
• Update your contact preferences

ABOUT CANCER

GET INVOLVED

NEWS & RESOURCES

FUNDING & RESEARCH

You are here

Longer, better lives: A manifesto for cancer research and care

Our manifesto sets out the measures and commitments the next government can make to help prevent 20,000 cancer deaths every year by 2040.

Are you a politician, political adviser, health leader or supporter?

Download the manifesto

Are you a civil servant, policymaker or health expert?

Table of contents

Read time : 3 minutes

1.  We’ve made huge progress on cancer in the past 50 years

In the 1970s, only 1 in 4 people survived their cancer for 10 years or more. Now, twice as many survive.

Since the mid-1980s, over a million lives have been saved.

This is all thanks to the power of research, improvements in healthcare and the tireless efforts of NHS staff. 

2. But cancer is still the defining health issue of our time

Cancer affects people in every family and every constituency. Nearly 1 in 2 of us will get cancer in our lifetimes* 

We lag behind other comparable countries. A decade ago, England and Denmark were improving cancer outcomes at broadly the same rate. But now, with consistent funding and long-term strategies, Denmark have raced ahead.

(*Cancer Research UK, Lifetime risk of cancer. Available at: cruk.org/lifetimerisk )

3. The challenge is only growing

As our population grows and ages, the number of new cancer cases increases. By 2040, the number of new cases is projected to increase by around a quarter. That means around half a million new cases diagnosed each year. 

Cancer does not affect people equally – more than 33,000 cases each year across the UK are attributable to deprivation.

4. But so is the opportunity

We’re in a golden age for cancer research. New tools and technology mean we can do things in hours that used to take years, putting us on the brink of making huge leaps in how we prevent, diagnose and treat cancer.

Right now, the UK is a global leader in cancer research. 74% of people agree that the UK Government should increase its investment into cancer research and development.   

Improvements in cancer research and care would: 

• reduce health, social care and ‘informal’ care costs (care provided by family and carers)
• contribute to treating other health conditions
• have a positive impact on workforce productivity and quality of life

5. We can, and must, do better for people affected by cancer

We've succeeded before and we can succeed again.

With political will and leadership, we can all have more moments with the people we love.

6. Our aim is simple: longer, better lives

Our vision is a national commitment to reduce the cancer mortality rate by 15% by 2040 – preventing 20,000 cancer deaths every year.

Our manifesto and accompanying programme for the UK Government set out the immediate measures and long-term commitments an incoming Government can make to elevate UK cancer survival to amongst the best in the world.

7. Our five missions

We’re setting out the following missions to help us achieve our aim of longer, better lives., rebuild the uk’s global position in biomedical research..

We want the UK Government to pledge to back research : Set out a plan to close the more than £1bn funding gap for research into cancer over the next decade.

Prevent more cancers than ever before.

We want the UK Government to pledge to end cancers caused by smoking : Raise the age of sale of tobacco and fund a world-leading programme of measures to help people who smoke to quit.

Diagnose more cancers early.

We want the UK Government to pledge to drive earlier diagnoses: Implement proven measures, including a lung screening programme, to diagnose cancers early and reduce inequalities in access.

Bring innovation to patients more quickly and reduce inequalities.

We want the UK Government to end the waits : Ensure cancer wait time targets are met across England.

Build a national movement to beat cancer, sooner.

We want the UK Government to lead on cancer : Publish a long-term cancer strategy for England and establish a National Cancer Council, accountable to the prime minister, to drive cross-government action on cancer.

Read more about the missions

8. The time to act is now!

The public wants action: almost 8 in 10 people in england think the government needs to develop a long-term and fully funded plan specifically for cancer., ahead of the general election, the next government must commit to change. .

Download social media assets

 Read the technical annex for the manifesto and programme for UK Government

Are you a campaigner or volunteer? Join us in telling party leaders to back our calls and make cancer a priority.

Our team is working tirelessly to beat cancer – but your support has never been more important

Take action

Our experts

View our team page

Meet the team

Send us an email

Follow us on X

See the latest updates on X

What is our research strategy?

Our Research Strategy sets out five strategic aims that guide us towards funding the best research to achieve our vision - to see a day when no life is cut short by cancer. We believe this can only be achieved through research, by starting new discoveries worldwide. 

Worldwide Cancer Research sits at the very start of the research journey. 

We back brand new ideas and support scientists to ask bold new questions about how cancer works. Are you a researcher looking for funding that would like to know more? 

Explore our information for researchers

Our strategic aims:

We were founded on the principle that we would support research that seeks to answer the difficult questions in cancer biology. We are looking for innovative and truly novel ideas that have the potential to revolutionise our understanding of cancer and how to beat it. 

We support discovery research (often called ‘basic and translational’) but do not prioritise any field of research within this; we welcome research that draws on epidemiological, behavioural and clinical data to provide a starting point for a new avenue of research. Multidisciplinary or discipline-hopping projects are encouraged where this helps stimulate innovation. 

We will support any researcher with a brilliant idea, no matter where in the world they are based. 

To back the best ideas we can, we take an unbiased approach to funding and cast the net as widely as possible.

One of our founding principles is to tackle the unmet need in cancer research. This means we are looking to support research that; explores brand new concepts and approaches; advances our understanding of cancer with the potential to open up new areas of cancer research; and establishes the first step in a research journey that could one day provide new and better ways to prevent, diagnose and treat cancer. 

Our unbiased approach means that we will support research tackling any or all types of cancer, recognising that the greatest advances in cancer research often impact on more than one type and that cancer research should not be artificially limited. We encourage research into cancers that desperately need it – where outcomes for patients are low or haven’t seen significant improvement. 

Our current annual investment in new research projects is around £6 million. This means that we can only fund some of the brilliant ideas put forward by researchers. Our goal is to grow this investment every year so that no brilliant idea is lost. 

Our focus on discovery research and helping scientists to explore brand new concepts and approaches, sets in motion the journey towards clinical trials, and ultimately, new tests and treatments that impact the lives of people with cancer.  

By kick-starting new avenues of research all over the world, we have already seeded medical advances that are saving lives today, and we will continue doing that for the future. Success from a Worldwide Cancer Research grant is the generation of the solid initial findings required to secure downstream funding from other sources. 

In the 40 years since we started funding research, cancer survival rates have doubled. But nearly 10 million people still die every year from cancer. And while some cancers have seen dramatic improvements in survival, others have not. By funding the most innovative, exciting and daring research all over the world, we will ensure that survival rates continue to improve for all cancers.  

There is a trend for funding agencies to focus on applied and translational research and increasingly neglect discovery research. That is a huge error in the long run. You cannot build a house only with a roof. You need the groundwork. Some of the coolest scientific breakthroughs, with major impact for humankind, were the result of what we call basic science.

Our funding criteria

To help us fulfil the aims of our Research Strategy, and to ensure we realise our vision of no life cut short by cancer, we are looking for projects that meet the following funding criteria:

We are looking for innovative research that takes intellectual risks. To us, that means helping researchers turn their bold idea into reality. And if there is a risk of failure, we are willing to take it, if the rewards for success are worth it. 

We want to see ideas which have the potential to start new lines of research and to tell us something new about cancer and how it could be prevented, diagnosed or treated. 

We want to make the most of our supporters’ generous donations by funding standalone research projects. Projects should seek to answer a focused research question, not be an incremental piece of research tied to a larger programme grant. 

We are looking for ideas that excite. The ones that make us go, “I wish I had thought of that”. We are looking for proposals with a creative approach to answering fundamental questions that could change how we think about cancer. Often these are ideas that other funders may overlook. 

We want to see the most exciting and creative new ideas, but we are also responsible stewards of our supporters’ donations.  We need to see robust scientific reasoning and appropriate solid methodology to back it up. The aims of a project should be feasible with the time and resources requested, and with the expertise of the research team. 

We support blue-sky thinking in research and want to direct funding towards projects that could transform an area of cancer research or one day have a major impact on the lives of people with cancer. While impact on cancer patients is a priority for us and our supporters, we recognise that important discoveries take time to bear fruit and that it may be many years before the research leads to lives saved or improved. 

Will you fund more bold research?

We simply could not back the bright ideas that will lead to new cancer cures without your help. 

Our research projects

Explore the bright ideas we are funding

The projects seeking to answer big questions about any type of cancer, anywhere in the world. 

We want to hear your best ideas

Information for researchers

We fund discovery research. Wherever you are in the world, and whatever type of cancer you research - we may be able to support you with a project grant.

Together we are beating cancer

• Cancer types
• Breast cancer
• Bowel cancer
• Lung cancer
• Prostate cancer
• Cancers in general
• Clinical trials
• Causes of cancer
• Coping with cancer
• Managing symptoms and side effects
• Mental health and cancer
• Money and travel
• Death and dying
• Cancer Chat forum
• Health Professionals
• Cancer Statistics
• Cancer Screening
• Learning and Support
• NICE suspected cancer referral guidelines
• Make a donation
• By cancer type
• Leave a legacy gift
• Donate in Memory
• Find an event
• Race for Life
• Charity runs
• Charity walks
• Search events
• Relay for Life
• Volunteer in our shops
• Help at an event
• Help us raise money
• Campaign for us
• Do your own fundraising
• Fundraising ideas
• Get a fundraising pack
• Return fundraising money
• Fundraise by cancer type
• Set up a Cancer Research UK Giving Page
• Find a shop or superstore
• Become a partner
• Cancer Research UK for Children & Young People
• Our Play Your Part campaign
• Brain tumours
• Skin cancer
• All cancer types
• By cancer topic
• New treatments
• Cancer biology
• Cancer drugs
• All cancer subjects
• All locations
• By Researcher
• Professor Duncan Baird
• Professor Fran Balkwill
• Professor Andrew Biankin
• See all researchers
• Our achievements timeline
• Our research strategy
• Involving animals in research
• Research opportunities
• For discovery researchers
• For clinical researchers
• For population researchers
• In drug discovery & development
• In early detection & diagnosis
• For students & postdocs
• Our funding schemes
• Career Development Fellowship
• Discovery Programme Awards
• Clinical Trial Award
• Biology to Prevention Award
• View all schemes and deadlines
• Applying for funding
• Start your application online
• How to make a successful applicant
• Funding committees
• Successful applicant case studies
• How we deliver research
• Our research infrastructure
• Events and conferences
• Our research partnerships
• Facts & figures about our funding
• Develop your research career
• Recently funded awards
• Manage your research grant
• Notify us of new publications
• Find a shop
• Volunteer in a shop
• Donate goods to a shop
• Our superstores
• Shop online
• Wedding favours
• Cancer Care
• Flower Shop
• Our eBay store
• Shoes and boots
• Bags and purses
• We beat cancer
• We fundraise
• We develop policy
• Our global role
• Our organisation
• Our strategy
• Our Trustees
• CEO and Executive Board
• How we spend your money
• Early careers
• Your development

Cancer News

• For Researchers
• For Supporters
• Press office
• Publications
• Update your contact preferences
• About cancer
• Get involved
• Our research
• Funding for researchers

The latest news, analysis and opinion from Cancer Research UK

• Science & Technology
• Health & Medicine
• Personal Stories
• Policy & Insight
• Charity News

Your questions on our research strategy

29 March 2022

Following an incredible response to the launch of our refreshed research strategy last week, we take the opportunity to answer some questions from the research community

Last week we launched our refreshed Research Strategy . It sets out our scientific priorities and how we will work with you, our world-class research community, to achieve this.

It puts discovery research and excellence at the heart of what we’ll do. It’s built around 4 objectives – to discover, detect, prevent, and treat – so that progress in understanding the fundamental biology of cancer leads to new prevention measures, tests and treatments.

To achieve this, we will spend £1.5bn over the next five years, investing in creative people and transformational research. We will support research to reduce cancer inequalities and improve outcomes for everyone. And we’ll involve people affected by cancer in our work.

If you missed the launch broadcast, you can catch up here .

We were delighted that the strategy stimulated a vibrant discussion, with many insightful questions from the cancer research community. In fact, so many questions were asked that we didn’t get a chance to address them all. Here, we answer those questions we couldn’t get to during the event.

Q. Other than inspiring a diverse range of students to study stem subjects, what is CRUK doing to remove barriers to increase ethnic diversity in the workforce? We’re developing a range of measures to address the structural issues of equality and equity in cancer research.

Our 2021 EDI in Research Action Plan called for our institutes to each publish their own action plans, which they’ve done. We’ve set up a cross-CRUK institute EDI working group to share EDI strategy plans, best practice and approaches to joint issues such as increasing the diversity of students and the wider workforce, considering not only ethnicity, but also gender and socio-economic background.

On the wider question of how we are removing barriers, we will soon be publishing our annual report on progress against the action plan, which shows the progress we’ve made in many areas, including grant applications and awards, diversity in funding reviews as well as areas where we still need to go further.

In 2022-23 we have specific work planned to offer PhD scholarships to underrepresented groups, to support a Black in Cancer conference, and we’ll continue looking at gender and social mobility by working with In2Science and In2Research and providing mentoring programmes, such as Women of Influence.

Q. It is great that CRUK strives for inclusivity and to address EDI imbalance. The balance of your grant panels is important to achieve this – and should include both gender and encompass institutes outside of London. You have said that you’ll be removing independent reviewers’ comments for grants and extensively relying on panels instead to help diversity of people and thought. How exactly will this help? Expert review panels don’t represent a shift away from independent peer review – they’re just a different way of doing it, and we think having in-person discussions is generally a more valuable way of reviewing research applications than asking for written reviews. We considered the move away from written review carefully. We’ve observed that the change to review panels actually helps us to attract a greater diversity of people into our peer review processes – particularly representation from outside the UK, resulting in a good depth of discussions. The panel members remain independent of CRUK and we closely monitor the make-up of our panels to ensure we are including a diverse range of voices.

We advertise for members to join our review panels and committees. We select members based on the expertise required on the panel or committee and the diversity of backgrounds we believe is essential to fund the highest quality research. We strongly encourage those with relevant expertise to apply to join our review groups.

More information on changes to our peer review process .

Q. Relationships with universities is obviously very important with regard to diversity in research – how do we ensure diversity when early career researchers face contract precarity, with many of those choosing to leave academia? We recognise the challenges many early career researchers face, including precarity around transitional career points. We will be reviewing our careers-related offerings and working with our funded locations to improve the research environment in this regard. This will include setting expectations with institutions regarding support during and beyond fellowships, working with partners across the sector to support flexible career options and diverse career paths, and further consulting with our early research community on some of the issues they face. Q. What implications does the new CRUK Scotland Centre have for universities and health boards outside Glasgow and Edinburgh – I am thinking of Aberdeen? Glasgow and Edinburgh were the only CRUK centres in Scotland before our recent centres review, so there are no specific implications for other Scottish institutions. We award centre funding on a five-year basis; the upcoming funding period will run from April 2022 until March 2027. We were pleased that the newly formed Scotland Centre was successful in the independent review process. The funding for the new centre brings together the strengths of each preceding centre and extends the increasingly close working relationships between the two universities, that both also have partnerships across Scotland. The centre award does not preclude other places in Scotland from applying to be CRUK centres in the future nor from applying for funding through other routes that they are eligible for. Moreover, the centre will be a focal point for wider collaboration in Scotland particularly given its translational focus.

Q. Can you clarify whether the significant contraction of the CRUK centre network was a strategic decision or because of the substantial reduction in budget for the next quinquennium? While we did not set out to fund a specific number of centres, the budget for the 2022-27 funding period was around a third less than what we had for the 2017-22 period. Our overriding principles in determining which locations we funded were research quality and impact, and ensuring that sufficient funds were available to meet the centres’ aims. That necessitated some hard choices including significantly reducing the maximum amount of funding centres could apply for. Even with such measures, the funding could only go so far, resulting in the final make-up of the revised network.

Q. There has been a concentration of clinical academic training opportunities to fewer CRUK centres. Will the focus on diversity and inclusion mean that opportunities to undertake a CRUK funded PhD will be available in all parts the UK? We are continuing to support clinical academic training through our Clinical Academic Training Programme. The funding for this programme is not linked to CRUK centre awards, and so the recent centres quinquennial review had no impact on this. We’ll assess options towards the end of these programmes and will maintain our commitment to funding clinical academic training in research environments that are committed to advancing our EDI in research agenda. We also enable PhDs to be funded on our programme awards, which are of course nation-wide in reach.

Q. Can you elaborate on the fellowship opportunities for early career scientists? Specifically, will the Population Research Postdoctoral Fellowship be replaced with a new scheme? We’ll continue to offer a broad range of fellowship opportunities, including options for those looking to establish independence as a group leader and those building towards leadership in their field, for both clinical and non-clinical researchers. We want to support a diverse range of disciplines relevant to our research strategy through these schemes, including population researchers and we will take proactive steps to engage that community. Whilst we won’t be running a dedicated population research postdoc fellowship, there are now greater funding opportunities for postdocs in those fields through our population and prevention research committee, such as project grants that postdocs can apply for as leads.

Q. Will there be training posts that non-centres and non-ECMCs can apply for to address EDI? We are continuing our commitment to funding PhD training in excellent research environments. In our recent centres review, EDI plans were an integral part of the assessment so we will work with our centres to advance the EDI in research action plan over the next funding period. We will also continue to consider PhD posts on programmes and other strategic initiatives across our broader network and will be led by research excellence in determining these cases for support.

We’re supporting initiatives at both school and undergraduate level to attract and retain students in STEM subjects and are also developing plans for a positive action initiative at the PhD level to specifically target key underrepresented groups – we will announce more details in the next few months.

Q. Playing devil’s advocate (as a former clinician and now translational cancer researcher), I completely understand the ongoing focus on discovery science. However, many of our current standard-of-care cancer treatments have not been developed by such approaches with that level of underpinning science. Does an infatuation with discovery impede the funding and rapid clinical implementation of safe and effective re-purposed therapeutics? We believe that funding discovery research integrated with clinical research will increase understanding of which therapeutics should be the focus of repurposing. By increasing understanding of how and why therapies succeed or fail in clinical trials, or increasing effective stratification of sub-groups we can accelerate repurposing programmes, and increase the likelihood of successfully identifying new indications. Too many clinical studies lead to binary outcomes of drug efficacy without generating further understanding as to why a particular drug does or doesn’t work.

It is true the majority of therapeutics today have been developed and refined through iterative clinical studies, with improvements in outcomes made incrementally. This has led to great process in some cancers, for example breast cancer. However, this approach has not worked for all cancers. Making progress for all people with cancer will only be enabled by improving our understanding of how cancer starts, grows and spreads. This understanding will allow us to target, combine and sequence treatments much more effective. This will of course include repurposing of existing treatments alongside testing novel approaches. Q. Improving the clinical performance of currently available drugs could offer immediate impact for patients and address some of the inequality issues with cancer treatment. Therefore, why is improving drug delivery of cancer drugs not a priority for CRUK? Improving drug delivery is an important opportunity for improving outcomes. For example, the real challenges in understanding if and how certain drugs cross the blood brain barrier. This is another example of where discovery science and other disciplines such as bioengineering and nanotechnology have a vital part to play. This is very much within the remit of the new research strategy. Q. Where does behavioural science fit into the new research strategy? The pandemic has indicated that it plays an important role in public health. Will we get an appropriate balance of clinical and non-clinical research funded? Behavioural science remains a crucial component of affecting change in health outcomes – we must understand the drivers of health-related behaviours and how to intervene in an effective and precise manner to deliver health benefit through prevention, detection and treatment. Our Early Detection and Diagnosis, and our Prevention and Population Research Committees will continue to explicitly call for behavioural research in those arenas. The CRUK strategic theme of discovery at the heart of what we do applies to behavioural research as much as to biomolecular research.

Q. Will there be any focus on funding researchers outside traditional cancer fields? Following our 2014 research strategy, we set up initiatives to attract those not currently working in cancer to bring their expertise and insight to bear on cancer questions – these included project awards in cancer immunology and multidisciplinary research. The new strategy highlights a growing appreciation of whole-body physiology and opportunities in data science, so we want to continue building new networks and attracting those from other disciplines. We want to look at the range of options to do this, such as continuing to fund through existing schemes, convening researchers to explore collaborative opportunities, and working with a greater range of partners.

Q. How are you assessing the impact of Grand Challenge grants. For the amount of funding, one would expect the bar is very high on judging it a success. Has the overall grand challenge approach had a significant impact on patient outcomes. Cancer Grand Challenges is focused on solving cancer’s toughest challenges. It was co-founded by CRUK, the US National Cancer Institute (NCI) and other funding partners, after assessment of the success and proof of principle demonstrated by CRUK’s Grand Challenge initiative, in which we looked at the impact of the scientific outputs.

As the initiative is challenge led, we will assess the success of Cancer Grand Challenges by measuring the progress made by funded teams against these challenges. There are currently seven multidisciplinary teams across six challenges, which are currently largely discovery and translation in nature. The first four teams (funded in 2017) are already demonstrating key success. For example, the Mutographs team has challenged the classical view that all carcinogens directly cause mutations and suggests that non-mutagenic agents play a greater role in tumour promotion than originally thought.

Cancer Grand Challenges is overseen by two independent committees, featuring world renowned cancer researchers, clinicians, behavioural scientists and people affected by cancer.

To look at the wider impact of the Cancer Grand Challenges initiative we will also look at its impact on our future leaders, global advocacy and the tools and collaborations produced as a result.

Q. CRUK have gone for big funding schemes – grand challenges and large centre grants – which places extensive grant funding in the hands of a relatively few number of PIs. Is this the right way to increase diversity of ideas and approaches? We will continue to support a large community of researchers at all career stages based on excellence. We have one of the largest national postdoctoral fellowship communities and a widely distributed network of funded researchers supported via many project and programme grants. Our centres’ funding supports many PIs. By funding core facilities, local infrastructure, providing local development funds and studentships individuals can bid for, we believe centres play a key role in generating novel and innovative approaches. It is also key to bringing in individuals with no current CRUK funding and those who don’t currently work in cancer research into the field.

Cancer Grand Challenges was set up to identify specific barriers which, if removed, would be transformative and unlock the potential for patient benefit by funding a portfolio of novel and innovative research to encourage multidisciplinary approaches and attract new thinking to cancer research. We encourage diverse teams working across a breadth of disciplines, including biomedical sciences, software development and technology, engineering and physical sciences, behavioural, health, population and social sciences.

So far we’ve funded seven teams,  featuring 73 research groups and spanning nine countries. Across these teams there are seven principal investigators, 60 co-investigators, over 240 researchers and 35 collaborators. It is a network of nearly 700 investigators convening to solve the biggest cancer challenges.

Q. Clinical research and access to trials should be at the heart of the NHS. Due to all the service issues, staff shortages and system pressures it feels like this is being forgotten. Less patients are being recruited to studies and hospitals cannot cope. Are CRUK going to look to address this for cancer patients? We totally agree that clinical trials for cancer patients should be a standard offering to patients throughout the UK. It is undeniable that clinical research has suffered throughout the pandemic, and even yet is struggling to recover to pre-pandemic levels of activity. Through our policy efforts we continue to lobby the UK government to increase investment in the NHS, to support the UK clinical workforce by providing more dedicated time for research and to take urgent action to accelerate the recovery of the clinical research portfolio.

Q. Are there any more specific objectives around engaging partners and industry to tackle paediatric/teenage/rare cancers where numbers are low and there are inequalities in paediatric access to drugs compared to adults? We recognise that it is vital to work with partners to combine expertise, resources, tools, funding, and more for paediatric cancer research, not only to supporting clinical trials and drug development, but also in discovery science and building capacity within the research community. We have engaged with multiple partners in the UK and globally who are very interested in research into cancers that affect children and young people and we are keen to work with other like-minded organisations.

We already have a strong track record of working in partnership in this area. In 2021 working with Children with Cancer UK, we co-funded the Cancer Research UK–Children with Cancer UK Innovation Awards. This funding is supporting five new teams of world-leading scientists, with up to £1m each, to embark on five very distinct research projects to improve our understanding of the underpinnings of children’s and young people’s cancers.

Working in collaboration with Stand Up To Cancer, we delivered an international funding call in 2020 to drive multidisciplinary, transatlantic collaboration and knowledge sharing. We funded 3 transatlantic teams for up to $1m.

Additionally, we also have a long-standing partnership with the devolved UK government health departments to support our ECMC Paediatric Network to deliver early phase clinical trials for children and young people with cancer.

We are further exploring how to drive industry engagement and develop research partnerships in order to progress science, technologies and treatments for the benefit of paediatric patients and will share new initiatives in due course.

Thanks to all those who submitted a question during the launch event!

Highlighted content

More like this, cancer research matters - entrepreneurial deep dive, video: professor arnold kriegstein on brain cancer, developmental biology and ever-evolving lab tech....